Background: Some previous studies found decreased concentrations of L-tryptophan (TRY) and increased L-kynurenine (KYN), or its metabolites, in the body fluids of subjects with major depressive disorder (MDD), sometimes in association with suicidal behavior. Such changes might indicate a shift of TRY away from serotonin production, possibly via the effects of inflammatory peptides which activate indoleamine-2,3-dioxygenase. However, these findings have been inconsistent and require replication. Methods: We used sensitive liquid-chromatography mass spectrometry methods to assay plasma concentrations of TRY, 5-hydroxyindoleacetic acid (5-HIAA), and KYN and its metabolites (anthranilic acid and xanthurenic acid). We compared 49 hospitalized, depressed subjects diagnosed with MDD (n = 37) or bipolar disorder (BD, n = 12), with (n = 22) or without (n = 27) previous suicide attempts, to 78 healthy, ambulatory controls of similar age and sex (total n = 127). Findings: Contrary to expectation, TRY plasma concentrations were higher, KYN plasma concentrations were lower, and their ratio much higher in depressed subjects, with no relationship to suicidal history. Concentrations of 5-HIAA and the kynurenine metabolites did not differ between depressed and healthy subjects. Conclusions: These findings are opposite to expectations and not consistent with a hypothesized increased conversion from TRY to KYN in depressed subjects. In addition, we found no evidence of altered production of serotonin as 5-HIAA concentration was unchanged. None of the observed changes was associated with a history of suicide attempt.

1.
Wichers MC, Maes M: Role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci 2004; 29: 11–17.
2.
Oxenkrug G: Serotonin-kynurenine hypothesis of depression: historical overview and recent developments. Curr Drug Targets 2013; 14: 514–521.
3.
Bay-Richter C, Linderholm KR, Lim CK, et al: Role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality. Brain Behav Immun 2015; 43: 110–117.
4.
Bryleva EY, Brundin L: Kynurenine pathway metabolites and suicidality. Neuropharmacology 2017; 112: 324–330.
5.
Erhardt S, Lim CK, Linderholm KR, et al: Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology 2013; 38: 743–752.
6.
Maes M, Verkerk R, Bonaccorso S, Ombelet W, Bosmans E, Scharpé S: Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sci 2002; 71: 1837–1848.
7.
Myint AM, Kim YK, Verkerk R, Scharpé S, Steinbusch H, Leonard B: Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord 2007; 98: 143–151.
8.
Myint AM, Schwarz MJ, Müller N: Role of the kynurenine metabolism in major depression. J Neural Transm 2012; 119: 245–251.
9.
Miller CL, Llenos IC, Cwik M, Walkup J, Weis S: Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. Neurochem Int 2008; 52: 1297–1303.
10.
Chen Y, Guillemin GJ: Kynurenine pathway metabolites in humans: disease and healthy states. Int J Tryptophan Res 2009; 2: 1–19.
11.
Gabbay V, Klein RG. Katz Y, et al: Possible role of the kynurenine pathway in adolescent depression with melancholic features. J Child Psychol Psychiatry Allied Discip 2010; 51: 935–943.
12.
Raison CL, Dantzer R, Kelley KW, et al: Immune responses and depression. Mol Psychiatry 2010; 15: 393–403.
13.
Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ: Kynurenines in the mammalian brain: when physiology meets pathology. Nature Rev Neurosci 2012; 13: 465–477.
14.
Clark SM, Pocivavsek A, Nicholson JD, et al: Reduced kynurenine pathway metabolism and cytokine expression in the prefrontal cortex of depressed individuals. J Psychiatry Neurosci 2016; 41: 1–9.
15.
Laugeray A, Launay JM, Callebert J, Surget A, Belzung C, Barone PR: Evidence for a key role of the peripheral kynurenine pathway in the modulation of anxiety- and depression-like behaviors in mice: focus on individual dif-ferences. Pharmacol Biochem Behav 201; 198: 161–168.
16.
Curzon G, Bridges PK: Tryptophan metabolism in depression. J Neurol Neurosurg Psychiatry 1970; 33: 698–704.
17.
Heyes MP, Saito K, Crowley JS, et al: Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 1992; 115: 1249–1273.
18.
Laugeray A, Launay JM, Callebert J, Surget A, Belzung C, Barone PR: Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression. Behav Brain Res 2010; 210: 84–91.
19.
Savitz J, Dantzer R, Meier TB, et al: Activation of the kynurenine pathway is associated with striatal volume in major depressive disorder. Psychoneuroendocrinology 2015; 62: 54–58.
20.
Meier TB, Drevets WC, Wurfel BE, et al: Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder. Brain Behav Immun 2016: 53: 39–48.
21.
Shader RI: Kynurenine – an old pathway retraced. J Clin Psychopharmacol 2006; 26: 351–352.
22.
Sublette ME, Galfalvy HC, Fuchs D, Lapidus M, Grunebaum MF, Oquendo MA, et al: Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behav Immun 2011; 25: 1272–1278.
23.
Bradley KAL, Case JAC, Khan O, et al: The role of the kynurenine pathway in suicidality in adolescent major depressive disorder. Psychiatry Res 2015; 227: 206–212.
24.
Quak J, Doornbos B, Roest AM, et al: Does tryptophan degradation along the kynurenine pathway mediate the association between pro-inflammatory immune activity and depressive symptoms? Psychoneuroendocrinology 2014; 45: 202–210.
25.
Sheehan DV, Lecrubier Y, Sheehan KH, et al: The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59: 22–33.
26.
Jones SH, Thornicroft G, Coffey M, Dunn G: A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 1995; 166: 654–659.
27.
Busner J, Targum SD: The Clinical Global Impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 2007; 4: 28–37.
28.
O’Carroll PW, Berman AL, Maris RW, Moscicki EK, Tanney BL, Silverman MM: Beyond the Tower of Babel: a nomenclature for suicidology. Suicide Life Threat Behav 1996; 26: 237–352.
29.
Silverman MM, Berman AL, Sanddal ND, O’Carroll PW, Joiner TE: Rebuilding the Tower of Babel: a revised nomenclature for the study of suicide and suicidal behaviors. Suicide Life Threat Behav 2007; 37: 264–277.
30.
Fazio F, Lionetto L Curto M, et al: Xanthurenic acid activates mGlu2/3 metabotropic glutamate receptors and is a potential trait marker for schizophrenia. Sci Rep 2016; 5: 17799–17813.
31.
Curto M, Lionetto L, Capi M, et al: Kynurenine pathway metabolites in cluster headache. J Headache Pain 2015; 16:A87.
32.
Quak J, Doornbos B, Roest AM, et al: Does tryptophan degradation along the kynurenine pathway mediate the association between pro-inflammatory immune activity and depressive symptoms? Psychoneuroendocrinology 2014; 4: 202–210.
33.
Dahl J, Andreassen OA, Verkerk R, et al: Ongoing episode of major depressive disorder is not associated with elevated plasma levels of kynurenine pathway markers. Psychoneuroendocrinology 2015; 56: 12–22.
34.
Vázquez GH, Camino S, Tondo L, Baldessarini RJ: Potential novel treatments for bipolar depression: ketamine, fatty acids, anti-inflammatory agents, and probiotics. CNS Neurol Disord Drug Targets 2017; 16: 858–869.
35.
Leonard BE: The concept of depression as a dysfunction of the immune system. Curr Immunol Rev 2010; 6: 205–212.
36.
Asberg M, Träskman L: Studies of CSF 5-HIAA in depression and suicidal behavior. Adv Exp Med Biol 1981; 133: 739–752.
37.
van Heeringen K, Mann JJ: The neurobiology of suicide. Lancet Psychiatry 2014; 1: 63–72.
38.
Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R: New “5-HT” hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 702–721.
39.
Asberg M, Traskman L, Thoren P: 5-HIAA in the cerebrospinal fluid: a biochemical suicide predictor? Arch Gen Psychiatry 1976; 33: 1193–1197.
40.
Bartoli F, Crocamo C, Trotta G, Bava M, Capuzzi E, Castagna G, et al: Testing the role of the antioxidant uric acid as a biomarker of suicidal ideation in subjects with major affective disorders: an exploratory study. Gen Hosp Psychiatry 2018; 51: 128–129.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.